N. Bernardini, A. Dattola, G. Caldarola, D. Orsini, C. Assorgi, Alessandra D’Amore, Giulia Maretti, A. Richetta, E. Tolino, N. Skroza, C. Potenza
{"title":"面部银屑病对双美珠单抗的快速反应：病例系列","authors":"N. Bernardini, A. Dattola, G. Caldarola, D. Orsini, C. Assorgi, Alessandra D’Amore, Giulia Maretti, A. Richetta, E. Tolino, N. Skroza, C. Potenza","doi":"10.7573/dic.2024-1-4","DOIUrl":null,"url":null,"abstract":"Psoriasis is a chronic inflammatory disease that can affect any part of the body but, when it appears in certain areas, like the face, it can have a very significant psychological impact. Biologics, in particular IL-17 and IL-23 drug inhibitors, have shown relevant clinical efficacy in the management of psoriatic lesions in difficult-to-treat areas. In post hoc analysis of phase III trials in plaque psoriasis, bimekizumab has shown safety and complete clearance of high-impact areas. However, these studies did not focus on the effect of bimekizumab on facial lesions. Therefore, this case series represents the first clinical real-life experience of rapid and successful management of facial psoriasis with bimeki-zumab","PeriodicalId":502654,"journal":{"name":"Drugs in Context","volume":"27 11","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Rapid response on facial psoriasis to bimekizumab: case series\",\"authors\":\"N. Bernardini, A. Dattola, G. Caldarola, D. Orsini, C. Assorgi, Alessandra D’Amore, Giulia Maretti, A. Richetta, E. Tolino, N. Skroza, C. Potenza\",\"doi\":\"10.7573/dic.2024-1-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Psoriasis is a chronic inflammatory disease that can affect any part of the body but, when it appears in certain areas, like the face, it can have a very significant psychological impact. Biologics, in particular IL-17 and IL-23 drug inhibitors, have shown relevant clinical efficacy in the management of psoriatic lesions in difficult-to-treat areas. In post hoc analysis of phase III trials in plaque psoriasis, bimekizumab has shown safety and complete clearance of high-impact areas. However, these studies did not focus on the effect of bimekizumab on facial lesions. Therefore, this case series represents the first clinical real-life experience of rapid and successful management of facial psoriasis with bimeki-zumab\",\"PeriodicalId\":502654,\"journal\":{\"name\":\"Drugs in Context\",\"volume\":\"27 11\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drugs in Context\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.7573/dic.2024-1-4\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs in Context","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7573/dic.2024-1-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
银屑病是一种慢性炎症性疾病，可影响身体的任何部位，但当它出现在某些部位（如面部）时，会对患者的心理造成极大的影响。生物制剂，尤其是 IL-17 和 IL-23 药物抑制剂，在治疗难治部位的银屑病皮损方面显示出了相关的临床疗效。在对斑块状银屑病 III 期试验的事后分析中，bimekizumab 显示了安全性，并完全清除了高影响区域。然而，这些研究并未关注 bimekizumab 对面部皮损的影响。因此，本系列病例代表了首次使用比美单抗快速、成功治疗面部银屑病的临床实际经验。
Rapid response on facial psoriasis to bimekizumab: case series
Psoriasis is a chronic inflammatory disease that can affect any part of the body but, when it appears in certain areas, like the face, it can have a very significant psychological impact. Biologics, in particular IL-17 and IL-23 drug inhibitors, have shown relevant clinical efficacy in the management of psoriatic lesions in difficult-to-treat areas. In post hoc analysis of phase III trials in plaque psoriasis, bimekizumab has shown safety and complete clearance of high-impact areas. However, these studies did not focus on the effect of bimekizumab on facial lesions. Therefore, this case series represents the first clinical real-life experience of rapid and successful management of facial psoriasis with bimeki-zumab
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
